Charles River Laboratories | CRL - Cash And Equivalent


Charles River Laboratories reported $192.02M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agilent USD 1.81B 49M Mar/2026
Align Technology USD 1.1B 42.76M Jun/2026
Bio-Rad Laboratories USD 517M 9.8M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Cardinal Health USD 3.94B 1.16B Mar/2026
Charles River Laboratories USD 192.02M 195K Jun/2026
Cigna USD 6.3B 742M Jun/2026
Concord Medical Services Hldg CNY 243.38M 85.1M Jun/2023
CVS Health USD 11.33B 1.79B Jun/2026
Danaher USD 4.35B 1.35B Jun/2026
Dentsply International USD 190M 136M Mar/2026
Elevance Health USD 10.23B 575M Jun/2026
Humana USD 6.89B 1.94B Jun/2026
Illumina USD 1.09B 329M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Intrexon USD 9.34M 1.77M Jun/2024
IQVIA Holdings USD 1.91B 38M Jun/2026
Laboratory Of America USD 141.8M 839.3M Jun/2026
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Lonza CHF 719M 188M Dec/2025
McKesson USD 5.16B 1.19B Jun/2026
Merck EUR 2.74B 415M Mar/2026
Mettler Toledo International USD 51.38M 9.19M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
Quest Diagnostics USD 626M 233M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
United Therapeutics USD 1.8B 523.5M Jun/2026
UnitedHealth USD 31.47B 239M Jun/2026
Veradigm USD 492.6M 7.57M Sep/2022
Waters USD 539M 77M Jun/2026
West Pharmaceutical Services USD 435.8M 85.6M Jun/2026